GSK will no longer supply or distribute Imvamune.

Bavarian Nordic agreed with GlaxoSmithKline not to pursue a collaboration for the production and marketing of Imvamune®, a third-generation smallpox vaccine under development.

The companies had previously signed a memorandum to ensure sufficient production capacity from several facilities and distribution of imvamune to various international markets at a time where Bavarian Nordic’s production facility was not established. Now Bavarian Nordic says it has the capacity to produce the expected RFP-III order.

Previous articleCSL Behring and Bayer Extend Agreement Related to Hemophilia
Next articleEuroscreen and Cephalon Extend GPCR Discovery Collaboration through 2009